Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Receivables (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Change in Receivables data on record, last reported at $1.7 million in Q2 2025.

  • For Q2 2025, Change in Receivables rose 200.72% year-over-year to $1.7 million; the TTM value through May 2025 reached $2.3 million, down 30.68%, while the annual FY2025 figure was $2.3 million, 30.68% down from the prior year.
  • Change in Receivables reached $1.7 million in Q2 2025 per LFCR's latest filing, up from $918000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $12.5 million in Q1 2023 and bottomed at -$12.5 million in Q4 2022.
  • Average Change in Receivables over 5 years is $1.1 million, with a median of $1.7 million recorded in 2025.
  • Peak YoY movement for Change in Receivables: surged 858.02% in 2021, then plummeted 1420.18% in 2022.
  • A 5-year view of Change in Receivables shows it stood at $3.5 million in 2021, then plummeted by 461.2% to -$12.5 million in 2022, then surged by 128.78% to $3.6 million in 2023, then surged by 60.33% to $5.8 million in 2024, then tumbled by 71.18% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $1.7 million in Q2 2025, $918000.0 in Q1 2025, and $5.8 million in Q4 2024.